Technical Analysis for VCEL - Vericel Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.06% | |
Bollinger Band Squeeze | Range Contraction | 0.06% | |
NR7 | Range Contraction | 0.06% | |
Gapped Up | Strength | 0.06% | |
Bollinger Band Squeeze | Range Contraction | 0.89% | |
Stochastic Reached Oversold | Weakness | 0.89% | |
Strong but Oversold | Other | 0.89% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.89% | |
Lower Bollinger Band Touch | Weakness | 0.89% | |
Oversold Stochastic | Weakness | 0.89% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Reversed from Down | 12 minutes ago |
Gap Down Closed | about 1 hour ago |
60 Minute Opening Range Breakout | about 2 hours ago |
Gap Down Partially Closed | about 3 hours ago |
Down 3% | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 05/10/2023
Vericel Corporation Description
Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Stem Cell Cell Therapy Heart Failure Knee Burns Myopathy Cardiomyopathy Cartilage Osteochondritis Dissecans Severe Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 35.73 |
52 Week Low | 17.31 |
Average Volume | 242,023 |
200-Day Moving Average | 27.46 |
50-Day Moving Average | 31.44 |
20-Day Moving Average | 33.27 |
10-Day Moving Average | 33.39 |
Average True Range | 1.38 |
RSI (14) | 51.69 |
ADX | 15.07 |
+DI | 23.27 |
-DI | 20.22 |
Chandelier Exit (Long, 3 ATRs) | 31.61 |
Chandelier Exit (Short, 3 ATRs) | 35.16 |
Upper Bollinger Bands | 34.76 |
Lower Bollinger Band | 31.78 |
Percent B (%b) | 0.39 |
BandWidth | 8.95 |
MACD Line | 0.38 |
MACD Signal Line | 0.60 |
MACD Histogram | -0.2215 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 34.21 | ||||
Resistance 3 (R3) | 34.20 | 33.77 | 33.99 | ||
Resistance 2 (R2) | 33.77 | 33.45 | 33.77 | 33.92 | |
Resistance 1 (R1) | 33.35 | 33.24 | 33.14 | 33.36 | 33.85 |
Pivot Point | 32.92 | 32.92 | 32.81 | 32.92 | 32.92 |
Support 1 (S1) | 32.50 | 32.60 | 32.29 | 32.51 | 32.01 |
Support 2 (S2) | 32.07 | 32.39 | 32.07 | 31.94 | |
Support 3 (S3) | 31.65 | 32.07 | 31.87 | ||
Support 4 (S4) | 31.66 |